Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

Abstract Understanding mechanisms of resistance to active therapies is crucial for developing more effective treatments. Here, we investigate resistance to anti-EGFR and anti-VEGF plus chemotherapy treatment in colorectal cancer (CRC) patients from the IMblaze370 trial (NCT02788279). While anti-VEGF...

Descripció completa

Dades bibliogràfiques

Autors principals:	Xueping Qu, Habib Hamidi, Radia M. Johnson, Ethan S. Sokol, Eva Lin, Cathy Eng, Tae Won Kim, Johanna Bendell, Smruthy Sivakumar, Benjamin Kaplan, Felipe de Sousa e Melo, Andrew Mancini, Matthew Wongchenko, Yi Shi, David Shames, Yibing Yan, Fortunato Ciardiello, Carlos Bais
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-05-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-025-59588-3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!